利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.02 秒)

    Agents affecting thrombosis and hemostasis
    1.
    发明申请
    Agents affecting thrombosis and hemostasis 审中-公开
    影响血栓形成和止血的药物

    公开(公告)号：US20040072757A1

    公开(公告)日：2004-04-15

    申请号：US10712332

    申请日：2003-11-13

    申请人： COR Therapeutics, Inc.

    发明人： David L. Wolf ,  Uma Sinha

    IPC分类号： A61K038/37

    CPC分类号： C12N9/6464 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12N9/647 ,  C12Y304/21006 ,  C12Y304/21069

    摘要： Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

    摘要翻译： 短暂失活的血液因子的类似物可用于治疗以血栓形成为特征的疾病。 此外，在血清中产生活性血因子但具有延长半衰期的活化血液因子的修饰形式可用于治疗嗜血性病症。 血液因子的这些修饰形式可以是在体内缓慢脱酰基化的酰化形式。

    Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
    2.
    发明申请
    Inhibitory immunoglobulin polypeptides to human PDGF beta receptor 审中-公开
    对人PDGFβ受体的抑制性免疫球蛋白多肽

    公开(公告)号：US20030228307A1

    公开(公告)日：2003-12-11

    申请号：US10439168

    申请日：2003-05-16

    申请人： COR Therapeutics Inc. ,  Millennium Pharmaceuticals Inc.

    发明人： Vanitha Ramakrishnan ,  Maria Amelia Escobedo ,  Larry J. Fretto

    IPC分类号： A61K039/395 ,  C07K016/44 ,  C07K016/28

    CPC分类号： C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2317/34 ,  C07K2317/73

    摘要： The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

    摘要翻译： 本发明涉及特异性结合人β型PDGF受体的细胞外结构域的免疫球蛋白多肽。 免疫球蛋白多肽与受体的结合抑制PDGF诱导（或刺激的）受体活化，如通过受体磷酸化和二聚化的抑制以及通过抑制PDGF介导的有丝分裂发生，趋化性和显示人PDGF型β受体的细胞的迁移所表明的 在细胞表面。 编码免疫球蛋白多肽的核酸也包含在本发明中。 免疫球蛋白多肽具有诊断和治疗用途。

    Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction
    4.
    发明申请
    Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction 审中-公开
    鉴定Bap-1，一种结合整联蛋白并参与整合素介导的信号转导的蛋白质

    公开(公告)号：US20020164698A1

    公开(公告)日：2002-11-07

    申请号：US09991888

    申请日：2001-11-26

    申请人： COR Therapeutics, Inc.

    发明人： Shengfeng Li ,  David R. Phillips

    IPC分类号： C12N009/12 ,  C12P021/02 ,  C12N001/21 ,  C12N005/06 ,  C07H021/04

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： The present invention provides the amino acid and nucleotide sequence of a protein that binds to null3 integrins, nullIIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling

    摘要翻译： 本发明提供了结合β3整联蛋白，αIIb和Src激酶并参与整联蛋白介导的信号传导的蛋白质的氨基酸和核苷酸序列。 基于该公开内容，本发明提供了用于鉴定阻断整联蛋白介导的信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导来调节生物学和病理学过程的试剂的方法以及阻断整联蛋白介导的信号传导

    Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
    6.
    发明申请
    Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor 审中-公开
    重组C140受体，其激动剂和拮抗剂，以及编码受体的核酸

    公开(公告)号：US20030018184A1

    公开(公告)日：2003-01-23

    申请号：US10127691

    申请日：2002-04-23

    申请人： COR THERAPEUTICS, INC.

    发明人： Johan Sundelin ,  Robert M. Scarborough

    IPC分类号： C07K014/715 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/723 ,  G01N2333/726 ,  G01N2500/00

    摘要： Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.

    摘要翻译： 编码C140细胞表面受体的核酸分子已被克隆并测序。 C140受体DNA的可用性允许重组产生可在细胞表面（包括卵母细胞）上产生的C140受体。 核酸分子可用于检测影响C140受体活性的物质，即受体激动剂或拮抗剂。 此外，阐明C140受体的结构允许设计可用于此类测定中的激动剂和拮抗剂化合物。 C140受体的可用性还允许产生与C140受体的一个或多个抗原表位特异性免疫反应的抗体。

    Modulation of integrin-mediated signal transduction
    8.
    发明申请
    Modulation of integrin-mediated signal transduction 审中-公开
    整合素介导的信号转导调控

    公开(公告)号：US20030059852A1

    公开(公告)日：2003-03-27

    申请号：US09801089

    申请日：2001-03-08

    申请人： COR Therapeutics, Inc.

    发明人： David R. Phillips ,  Deborah Ann Law ,  Lisa Nannizzi Alaimo

    IPC分类号： G01N033/53 ,  A61K038/16 ,  C07K014/00

    CPC分类号： C07K14/70546

    摘要： The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the null-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block integrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.

    摘要翻译： 本发明公开了信号蛋白结合所需的整联蛋白β亚单位的细胞质酪氨酸残基的磷酸化。 本发明提供鉴定涉及整联蛋白介导的信号传导的信号载体的方法，鉴定阻断整联蛋白介导信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导调节生物和病理过程的试剂的方法，以及阻断整合素介导的信号传导的试剂。